Drug Trial Radar · NCT06868277
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
Last checked: Nov 20, 2026Latest source record: Sep 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
830
Planned (sponsor's estimate)
Start
Apr 10, 2025
Primary completion
Jan 17, 2030
Study completion Dec 2, 2030
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Mar 10, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of ARTEMIDE-Lung04 is to assess the efficacy and safety of rilvegostomig compared with pembrolizumab monotherapy as 1L treatment in participants with mNSCLC and whose tumors express PD-L1.
Conditions
- Carcinoma, Non-Small Cell Lung
Interventions
RilvegostomigBiological
Administered intravenously (IV) on Day 1 of each 21-day cycle
PembrolizumabBiological
Administered intravenously (IV) on Day 1 of each 21-day cycle
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Survival (OS)Time frame: Up to approximately 5 years
- Progression-Free Survival (PFS)Time frame: Up to approximately 5 years
Locations
304 sites in 27 countries. Site status is shown where the registry gives one.
Research Site
La Mesa, California · Not yet recruiting
Research Site
Los Alamitos, California · Not yet recruiting
Research Site
Newark, Delaware · Recruiting
Research Site
Bay Pines, Florida · Recruiting
Research Site
Clearwater, Florida · Recruiting
Research Site
Gainesville, Florida · Recruiting
Research Site
St. Petersburg, Florida · Recruiting
Research Site
Marietta, Georgia · Recruiting
Research Site
Chicago, Illinois · Recruiting
Research Site
Decatur, Illinois · Recruiting
Research Site
Des Moines, Iowa · Recruiting
Research Site
Waterloo, Iowa · Not yet recruiting
Research Site
Leawood, Kansas · Recruiting
Research Site
Lexington, Kentucky · Not yet recruiting
Research Site
Owensboro, Kentucky · Recruiting
Research Site
Bethesda, Maryland · Recruiting
Research Site
Frederick, Maryland · Recruiting
Research Site
Silver Spring, Maryland · Recruiting
Research Site
Towson, Maryland · Recruiting
Research Site
Saginaw, Michigan · Not yet recruiting
Research Site
Bridgeton, Missouri · Recruiting
Research Site
Lincoln, Nebraska · Recruiting
Research Site
Reno, Nevada · Recruiting
Research Site
Paramus, New Jersey · Not yet recruiting
Research Site
Buffalo, New York · Recruiting
Research Site
East Syracuse, New York · Recruiting
Research Site
Fresh Meadows, New York · Recruiting
Research Site
Rochester, New York · Not yet recruiting
Research Site
Westbury, New York · Recruiting
Research Site
Canton, Ohio · Not yet recruiting
Research Site
Fountain Hill, Pennsylvania · Recruiting
Research Site
Kittanning, Pennsylvania · Not yet recruiting
Research Site
Philadelphia, Pennsylvania · Recruiting
Research Site
Round Rock, Texas · Not yet recruiting
Research Site
Aberdeen, Washington · Recruiting
Research Site
Renton, Washington · Not yet recruiting
Research Site
Charleston, West Virginia · Recruiting
Research Site
Morgantown, West Virginia · Recruiting
Research Site
Schofield, Wisconsin · Not yet recruiting
Research Site
CABA, Argentina · Recruiting
Showing 40 of 304 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.